Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis. What's more, the coverage gap puzzled people who often paid different amounts for ...

The best Medicare plans for cancer patients are a Medigap Plan G from AARP and a Medicare Part D plan from Wellcare. Alternatively, if your cancer diagnosis means you can't qualify for Medigap, choose a Medicare Advantage plan from Aetna. In both cases ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare

An analysis of oncology drugs approved in the United States found that Medicare spending was predominantly driven by the market, not a drug’s therapeutic value.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Like mammograms, breast ultrasounds are covered under Medicare Part B. If you have a Medicare Advantage (Part C) plan instead of Original Medicare (parts A and B), your plan should similarly cover this screening. Some plans may even offer additional benefits that could reduce your costs further.

The first openly trans member of Congress reflects on how her experience with love and loss taught her to pursue change from a place of compassion.

Prosecutors allege Adam Wayne Owens violated an anti-kickback statute in a scheme to provide genetic cancer testing for Medicare recipients.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.